Navigation Links
Stem Cell Orthopedic Applauds Use of Stem Cell Therapy for Spinal Injuries
Date:7/22/2013

(PRWEB) July 22, 2013

The Institute of Regenerative and Molecular Orthopaedics (IRMO), world-renowned stem cell therapy experts, applauds the use of stem cell therapy for treatment of spinal injuries. In recent times, stem cell therapy has been increasingly sought after to support treatments of various injuries, especially in the sports world. Its use in repairing spinal injuries comes as good news to the thousands of Americans currently living with spinal cord injuries who are seeking the latest in breakthrough medical solutions.

Stem cell therapy is of the most exciting and promising treatments in modern medicine. Inroads are made every day, as the many applications of stem cell treatments become better understood by medical professionals around the world. Experts, like Dr. Joseph Purita of the Institute of Regenerative and Molecular Orthopaedics, have been utilizing stem cell treatments for many years to treat sports injuries.

Recent scientific and technological advancements have made stem cell extraction relatively inexpensive and accessible. Today, medical professionals have unprecedented access to these remarkable cells and are increasingly applying them in new ways to better aid in the body’s repair process. This includes advances in platelet rich plasma therapy (PRP), a process that takes a concentration of a person’s own plasma and injects it into areas in need of new growth and tissue repair.

The use of stem cell therapy in the treatment of spinal cord injuries presents probably the biggest challenge yet for proponents of the treatment. Researchers are increasingly using stem cells to hopefully better understand its capabilities. The hope for spinal cord injuries is that one day stem cells can be used to generate new passageways for nerve signals to connect to muscles. The more stem cells are used for treatment in spinal cord injuries, the closer the medical field will be to fulfilling this promise.

Headed by the world-renowned stem cell treatment pioneer, Dr. Purita, the Institute of Regenerative and Molecular Orthopaedics is continually advancing the world of stem cell therapy treatments. They are one of the few orthopedic practices in existence that utilizes stem cell therapy, and PRP therapy, with orthopedic surgery to maximize a patient’s recovery outcome. As more stem cell treatments are being used to treat spinal injuries, Dr. Purita and his group look forward to seeing what great strides are made in battling the crippling condition in the near future.

About Stem Cell Orthopedic:
The Institute of Regenerative and Molecular Orthopaedics (IRMO) is a world-class orthopedic practice and stem cell facility staffed with seasoned board certified orthopedic surgeons. They differ from most orthopedic practices because they offer stem cells and platelet rich plasma (PRP) therapy in conjunction with surgery or as alternative to surgical procedures. They utilize state-of-the-art technology and the latest in stem cell research to best treat their patients. IRMO uses hematopoietic stem cells (HSC), which are found circulating in blood, fat, and bone marrow, to help repair the body. They are headed by Medical Director, Dr. Joseph Purita, a world-renowned pioneer in laser orthopedic surgery and graduate of the esteemed Georgetown University Medical School. For more information, visit http://www.stemcellorthopedic.com/ or follow them on Facebook, Twitter, or YouTube.

Read the full story at http://www.prweb.com/releases/2013/7/prweb10946780.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Providence Health & Services Inks Deal with Remedy Informatics for Orthopedic and Stroke Registries
2. Regenerative Sciences Receives $2M Investment for Orthopedic Stem Cell Initiatives
3. OHK Medical Devices to Exhibit at 2013 American Academy of Orthopedic Surgeons (AAOS) in Chicago
4. Histogen Creates PUR Biologics, a Joint Venture Developing Next-Generation, Biologic Solutions in Orthopedic Applications
5. US Market for Orthopedic Braces and Supports
6. West Wireless Health Institute Applauds House Passage of Bill to Streamline FDA Medical Device Approval Process, Expedite Mobile Medical App Guidance
7. Americord Applauds Study on Stem Cell Therapy for Congenital Heart Defects
8. Gene Therapy - Technologies, Markets and Companies
9. Studies Assess Hydroxyurea Therapy and Pre-Operative Transfusions for Patients with Sickle Cell Disease
10. TrovaGene, Inc. Obtains Exclusive License to Novel Mutations Associated with Prognosis and Chemotherapy Response in Leukemia
11. Amsterdam Molecular Therapeutics Receives US Orphan Designation for Hemophilia B Gene Therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... WA (PRWEB) , ... June 23, 2016 , ... ... announces the release of its second eBook, “Clinical Trials Patient Recruitment and Retention ... recruitment and retention in this eBook by providing practical tips, tools, and strategies ...
(Date:6/23/2016)... , June 23, 2016   Boston Biomedical ... novel compounds designed to target cancer stemness pathways, ... been granted Orphan Drug Designation from the U.S. ... of gastric cancer, including gastroesophageal junction (GEJ) cancer. ... designed to inhibit cancer stemness pathways by targeting ...
(Date:6/23/2016)... June 23, 2016 A person commits a crime, ... scene to track the criminal down. An outbreak ... and Drug Administration (FDA) uses DNA evidence to track down ... Sound far-fetched? It,s not. The FDA has increasingly used ... investigations of foodborne illnesses. Put as simply as possible, whole ...
(Date:6/23/2016)... ... June 23, 2016 , ... Charm Sciences, Inc. ... test has received AOAC Research Institute approval 061601. , “This is another AOAC-RI ... stated Bob Salter, Vice President of Regulatory and Industrial Affairs. “The Peel Plate ...
Breaking Biology Technology:
(Date:4/28/2016)... First quarter 2016:   , Revenues amounted ... quarter of 2015 The gross margin was 49% (27) ... the operating margin was 40% (-13) Earnings per share ... operations was SEK 249.9 M (21.2) , Outlook   ... M. The operating margin for 2016 is estimated to ...
(Date:4/15/2016)... Research and Markets has announced ... 2016-2020,"  report to their offering.  , ... global gait biometrics market is expected to grow ... 2016-2020. Gait analysis generates multiple variables ... to compute factors that are not or cannot ...
(Date:3/29/2016)... March 29, 2016 LegacyXChange, Inc. ... "LEGX" and SelectaDNA/CSI Protect are pleased to announce our ... in a variety of writing instruments, ensuring athletes signatures ... created collectibles from athletes on LegacyXChange will be assured ... the DNA. Bill Bollander , CEO ...
Breaking Biology News(10 mins):